NASDAQ:SPPI Spectrum Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.77 -0.01 (-1.28%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.74▼$0.8050-Day Range$0.70▼$0.9752-Week Range$0.60▼$3.83Volume1.66 million shsAverage Volume3.58 million shsMarket Capitalization$138.59 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spectrum Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingModerate Buy2.75 Rating ScoreUpside/Downside679.6% Upside$6.00 Price TargetShort InterestHealthy12.10% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.94Based on 5 Articles This WeekInsider TradingSelling Shares$13.90 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.25 out of 5 starsMedical Sector500th out of 1,429 stocksPharmaceutical Preparations Industry210th out of 682 stocks 3.4 Analyst's Opinion Consensus RatingSpectrum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Spectrum Pharmaceuticals has a forecasted upside of 679.6% from its current price of $0.77.Amount of Analyst CoverageSpectrum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.10% of the float of Spectrum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSpectrum Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Spectrum Pharmaceuticals has recently decreased by 6.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpectrum Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpectrum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpectrum Pharmaceuticals has received a 74.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Spectrum Pharmaceuticals is -0.75. Previous Next 2.7 News and Social Media Coverage News SentimentSpectrum Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Spectrum Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for SPPI on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Spectrum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spectrum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,896.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.Percentage Held by Institutions58.51% of the stock of Spectrum Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectrum Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectrum Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpectrum Pharmaceuticals has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Spectrum Pharmaceuticals (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.Read More SPPI Stock News HeadlinesJune 26, 2022 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Raised to Hold at StockNews.comJune 16, 2022 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Downgraded by StockNews.com to "Sell"June 13, 2022 | finance.yahoo.comWe're A Little Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn RateJune 11, 2022 | americanbankingnews.comSpectrum Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of ($0.50) Per Share (NASDAQ:SPPI)June 10, 2022 | americanbankingnews.comCantor Fitzgerald Reiterates Neutral Rating for Spectrum Pharmaceuticals (NASDAQ:SPPI)June 9, 2022 | americanbankingnews.comSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to Post FY2023 Earnings of ($0.18) Per Share, Cantor Fitzgerald ForecastsJune 8, 2022 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Receives Buy Rating from JMP SecuritiesMay 14, 2022 | finance.yahoo.comSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): Is Breakeven Near?May 12, 2022 | seekingalpha.comSpectrum Pharmaceuticals, Inc. (SPPI) CEO Thomas Riga on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | finance.yahoo.comSpectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate UpdateMay 5, 2022 | finance.yahoo.comSpectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of DirectorsApril 11, 2022 | finance.yahoo.comSpectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for EflapegrastimApril 4, 2022 | finance.yahoo.comSpectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual MeetingSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(702) 835-6300Fax702-260-7405Employees163Year Founded2002Company Calendar Last Earnings11/10/2021Today7/01/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+419.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-158.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-190.00% Return on Assets-103.40% Debt Debt-to-Equity Ratio0.10 Current Ratio2.38 Quick Ratio2.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book2.65Miscellaneous Outstanding Shares180,087,000Free Float175,225,000Market Cap$138.59 million OptionableOptionable Beta2.24 Social Links Spectrum Pharmaceuticals Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Spectrum Pharmaceuticals stock. View analyst ratings for Spectrum Pharmaceuticals or view top-rated stocks. What is Spectrum Pharmaceuticals' stock price forecast for 2022? 4 analysts have issued twelve-month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI stock forecasts range from $4.00 to $10.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $6.00 in the next year. This suggests a possible upside of 679.6% from the stock's current price. View analysts' price targets for Spectrum Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Spectrum Pharmaceuticals' stock price performed in 2022? Spectrum Pharmaceuticals' stock was trading at $1.27 on January 1st, 2022. Since then, SPPI shares have decreased by 39.4% and is now trading at $0.7696. View the best growth stocks for 2022 here. When is Spectrum Pharmaceuticals' next earnings date? Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Spectrum Pharmaceuticals. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07. During the same period in the prior year, the business posted ($0.37) earnings per share. View Spectrum Pharmaceuticals' earnings history. Who are Spectrum Pharmaceuticals' key executives? Spectrum Pharmaceuticals' management team includes the following people: Mr. Thomas J. Riga, Pres, CEO & Director (Age 47, Pay $1.02M) (LinkedIn Profile)Ms. Nora E. Brennan, Exec. VP & Chief Financial Officer (Age 53, Pay $54.17k)Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 46, Pay $851.73k) (LinkedIn Profile)Dr. Francois J. Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 70, Pay $917.96k)Mr. Bimal R. Shah, VP of Corp. & Bus. Devel.Dr. Lyndah K. Dreiling M.B.A., M.D., Sr. VP of Clinical Devel. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among Spectrum Pharmaceuticals' employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Spectrum Pharmaceuticals' key competitors? Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of SPPI's competitors. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $0.77. How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $138.59 million. The biotechnology company earns $-158.63 million in net income (profit) each year or ($0.88) on an earnings per share basis. How many employees does Spectrum Pharmaceuticals have? Spectrum Pharmaceuticals employs 163 workers across the globe. When was Spectrum Pharmaceuticals founded? Spectrum Pharmaceuticals was founded in 2002. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for Spectrum Pharmaceuticals is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at [email protected], or via fax at 702-260-7405. This page (NASDAQ:SPPI) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
